Overview

OPAL - Insulin Glulisine, Diabetes Mellitus

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary objective: The primary study objective is to compare efficacy of Insulin glulisine, once a day at breakfast vs. Insulin glulisine given once a day at main meal in combination with insulin glargine + OAD in terms of change in HbA1c, from baseline to endpoint for the individual patient. The aim of the study is to demonstrate two-sided equivalence between the two therapy regimens receiving two different injection timing of Insulin glulisine. Secondary objective: Secondary study objectives are to compare efficacy and safety of Insulin glulisine, once a day at breakfast vs. Insulin glulisine given once a day at main meal in combination with insulin glargine + OAD in terms of: - Change of fasting-, pre-/2h-postprandial-, mean daily and nocturnal blood glucose (baseline to endpoint) - Change of fasting plasma glucose (baseline to endpoint) - Response rate: Responders will be those patients with HbA1c smaller than 7.0% at study endpoint - Insulin dose (rapid-acting, basal and total daily doses) - Weight, body-mass index - Hypoglycemic events - Adverse events
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc